Chinook Is Advancing Kidney Disease Goals With Surrogate Endpoints, Asian JV

 
• By Joseph Haas

Vancouver biotech is building a pipeline of candidates for rare, severe chronic kidney disease. It has an oral drug in Phase III and an antibody candidate in mid-stage development for IGA nephropathy.

Human Kidneys, 2d rendering
Chinook aims to offer precision kidney medicine on an international basis

More from Strategy

More from Business